NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.18 +0.04 (+28.57 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$0.14
Today's Range$0.15 - $0.22
52-Week Range$0.13 - $0.68
Volume2.31 million shs
Average Volume305,657 shs
Market Capitalization$62.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.78
Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSEAMERICAN:NAVB
CUSIP63937X10
Phone+1-614-7937500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-688.85%
Return on Equity-38.60%
Return on Assets-25.48%

Miscellaneous

EmployeesN/A
Outstanding Shares163,620,000
Market Cap$62.36 million

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) released its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.54 million for the quarter. Navidea Biopharmaceuticals had a negative net margin of 688.85% and a negative return on equity of 38.60%. View Navidea Biopharmaceuticals' Earnings History.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Navidea Biopharmaceuticals.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 5,070,929 shares, a drop of 2.1% from the July 13th total of 5,180,659 shares. Based on an average daily volume of 438,608 shares, the short-interest ratio is currently 11.6 days. Currently, 3.3% of the shares of the stock are sold short. View Navidea Biopharmaceuticals' Current Options Chain.

Who are some of Navidea Biopharmaceuticals' key competitors?

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:
  • Dr. Michael M. Goldberg, CEO, Pres & Director (Age 59)
  • Mr. Jed A. Latkin, COO, CFO, Sec. & Treasurer (Age 44)
  • Dr. Frederick O. Cope, Sr. VP & Chief Scientific Officer (Age 71)
  • Mr. William J. Regan, Chief Compliance Officer and Sr. VP of Global Regulatory Affairs & Quality (Age 66)
  • Ms. Sharon Correia, Sr. Director of Corp. Communications

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

Media stories about NAVB stock have been trending somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Navidea Biopharmaceuticals earned a coverage optimism score of 0.02 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.23 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Navidea Biopharmaceuticals.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.18.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $62.36 million.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.